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Results.  The  population  targeted  for  screening  consisted  of  65 405 migrants,  among 










problem over  the world.  Internationally,  an  estimated 
240 million  people  are  chronically  infected with  hep-
atitis  B,  and  approximately  780 000  persons  die  each 
year from hepatitis B infection − 650 000 from cirrho-
sis and liver cancer due to chronic hepatitis B infection 
and  another  130 000  from acute hepatitis B  [1]. Left 
untreated, persistent HBV infection leads to premature 
death due to cirrhosis or hepatocellular carcinoma in a 




of  living,  like  the United States, Canada and western 
Europe, its prevalence is low, while the highest rates of 



















per  additional  quality-adjusted  life-year  (QALY);  this 
study was based on an estimated prevalence of 2% [7].
Other  studies  suggest  that  screening  for  chronic 




cohort’s  lifetime,  and  is  likely  to  be moderately  cost-






hepatitis  B  would  receive  treatment  (as  opposed  to 
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the  introduction  of  screening  in  the Netherlands  [9]. 








claimed that economic  impact assessments  should  in-
clude a classification of the policy-maker’s information 
needs,  a  full  and  detailed  breakdown  of  resource  use 
and costs, and a list of expected health outcomes [10].
The aim of  this  study was  to draw up a cost-conse-
quence  analysis  of  HBV  screening  in  the  immigrant 




A  cost-consequence  analysis  of  HBV  screening 
strategies was  conducted  on  the  cohort  of  adult mi-
grants  (> 20 years of  age)  in  the province of Padua. 
The target population to undergo screening was drawn 
from  the  number  of  foreigners  resident  in  the  prov-
ince,  identifiable  from the municipal population  reg-
istry. The number of HBV carriers  discovered  in  the 
target population was estimated  from the prevalence 
of  HBV  for  each  nationality,  weighted  according  to 
the  sizes  of  the  groups  from  different  nations  living 
in the province. Table 1 shows the prevalence of HBV 
infection  among  immigrants  in  the  province  by  eth-
nicity.  The  prevalence  estimates were  obtained  from 
data on the HBV screening of 450 regular healthy im-
migrants residing in Padua, and referred to our clinic 






of  immigrants  in  Padua,  assessing  their  health  out-
comes and the related costs in two different scenarios: 









Scenario  2)  if  a  screening  program  for  immigrants 
was  implemented, we assumed that 40% of the target 




infected  immigrants  not  tested  for HBV  experienced 
the natural history of the disease while they remained 






titis  B;  3)  compensated  cirrhosis;  4)  decompensated 




tion  living  in  the  province  of  Padua,  followed  by  the 
treatment of eligible patients. People in the target pop-
ulation would be  invited by means of  a  letter written 
in  their  own  language,  containing  information  about 
the purpose of  the screening program and a prescrip-
tion  that  they  could  take  to  any nearby  laboratory  to 




We  assumed,  as  above  specified,  that:  i)  in  the  ab-
sence of screening, 10% of the population would spon-
taneously  be  tested  for  HBV  (personal  expert  com-
munication); and ii) in the event of a screening effort, 






tive  carriers  or  had  chronic  hepatitis  not  warranting 
treatment (HBV-DNA < 20 000 IU/ml, normal ALT or 
HBV-DNA > 20 000 IU/ml, and normal ALT with no 
risk  factors),  31.5% were  cases  of  chronic hepatitis B 
warranting treatment, and 3.5% had cirrhosis (personal 
expert  communication:  Lobello  &  Martinez).  In  the 
first year of treatment, we assumed that interferon ther-
apy could be administered to 50% of the patients and 






in  the  international  literature  and  expert  opinions,  as 
shown in Table 2. 
Costs
The  costs  were  estimated  from  the  Italian  public 
health  service’s  perspective,  taking  the  year  2010  for 





toring,  performed  monthly  during  the  first  year  and 
every 3 months thereafter. The costs of a sustained viro-
logical response were calculated assuming that patients 
























needed  three  on  their HBV DNA  transaminase  tests 






















The  target  population  for  the  screening  program 
consisted of 65 405 migrants, with a weighted rate of 




(26 162 *0.04972)  people were  expected  to  be  found 








ing program would prevent  565  cases/year  of  chronic 




with  screening  was  11 549 781.29  and  with  total  five 
year  cost  of  the  scenario without  an  active  screening 
approach was 3 574 822.
The  above  data  revealed  that  the  incremental  cost 
of  the  screening  strategy  was  €  7 974 959  over  the 














ysis  of  screening  immigrants  residing  in  the  province 
of Padua for HBV infection by comparison with a no 
screening strategy.











antiviral  treatments  reduces  the  long-term  morbid-
ity  and mortality  due  to  this  infection,  increasing  the 
Table 1
Target population [11] and prevalence of HBV by ethnicity (ex-
pert report: Lobello & Martinez)
Provenance Subjects 





Romania 20 903 0.05
Republic of  Moldova 7 893 0.05
Albania 5 913 0.04
Ukraine 1 425 0.04
Republic of  Macedonia 1 149 0.04
Bosnia and Herzegovina 929 0.04
Republic of Serbia 764 0.04
Croatia 645 0.04
Kosovo 328 0.04
Other Central and Eastern 
European countries
1 191 0.04






Other African States 1 691 0.07
Republic of China 4 376 0.10
Philippines 1 573 0.08
Bangladesh 967 0.02
Sri Lanka (ex-Ceylon) 765 0.04
India 626 0.04
Other countries in Asia 913 0.04
Total immigrants 65 405

























Annual estimated progression in the natural history of active hepatitis B and treatment-related annual transition estimates  
a) Annual  estimated progression in natural history of active hepatitis B
Initial state Evolution Progression/year (%) References
HBeAg+ HBeAg-
Hepatitis B Undetectable  HBV DNA 6.9 1.6 [13, 14]
Cirrhosis 2.7 6.2 [15]
Hepatocellular  carcinoma 0.4 0.4 [15]
Cirrhosis Cirrhosis decompensated 3.9 2.7 [16-18]
Hepatocellular  carcinoma 1.8 2.9 [16-18]
Death 4 4 [19]
Decompensated 
cirrhosis 
Liver transplant 6.6 6.6 [20]
Hepatocellular carcinoma 1.8 2.9 [15]
Death 26 26 [15]
Hepatocellular 
carcinoma 
Liver transplant 4 4 [20]
Death 35 35 [13, 14]
Liver transplant Death 5.1 5.1 [20]
b) Treatment-related annual transition estimates  















Cirrhosis 0.2 0.6 [13, 23, 24] 




HBsAg loss 3.2 (1year) 0 [26, 27]
Undetectable HBV DNA 76 (1year)
73  (cumulative 3-year probability)
93 (1year)
87 (cumulative 3-year 
probability)
[26, 27]
Cirrhosis 0.2 0.6 [13, 14, 23, 24]








Cirrhosis 2.7 6.2 [13- 15]




Undetectable HBV DNA 70.5 70.5 [29]





Decompensated cirrhosis 1.9 1.9 [13-15]
Hepatocellular carcinoma 1.6 1.6 [13-15]
Death 2.4 2.4 [13-15]
Cirrhosis  
(non-responder)
Decompensated cirrhosis 3.9 3.9 [15]
Hepatocellular carcinoma 1.8 2.9 [13-15]
Death 3.1 3.1 [13-15]
Decompensated 
cirrhosis
Liver transplant 3.3 3.3 [30]
Death 26 26 [13-15]
Hepatocellular 
carcinoma
Liver transplant 1.2 1.2 [30]
Death 35 35 [13-15]
Liver transplant Death 5.1 5.1 [31]

























of  its  early-stage  treatment  [38,  39]. New  treatments 
that reduce the viral load in the blood more effectively 
have  now  become  available,  and  could  avert  serious 














until  they  develop  symptoms  and  complications  [38]. 
Another study concluded that early care for hepatitis B 
by means of screening in a US cohort improved health, 
reduced  premature  deaths,  and  prevented  expensive 
complications,  making  it  highly  cost-effective  in  the 
long term [39]. 
From the economic point of view, the present study 
shows  a  higher  cost  of  the  screening  strategy  com-
pared  with  no  screening,  which  could  be  attributed 
to  the  resources  used  to  treat  patients  diagnosed  at 
an early stage. This outlay at a time when the disease 
could  still  be  reversible  and  curable  would  mean  a 
cost  reduction  for patients  in  its more advanced and 






with  a  screening  program  rose  from  €  1  960  872  in 




for  other  screening  programs.  For  example,  White 
found in 1995 that the mean annual cost of mammo-




fection or disease  is an important  issue to consider  in 
any economic assessment of  the cost and health con-
sequences of case-finding interventions [7]. In another 






Cost data: average cost of different stages of the disease and annual drug costs [32]
Annual costs (€, 2010) References




HBV DNA 12.10 [33]
Blood count 4.75 [33]
Transaminases (AST, ALT) 5.3 [33]
Specialist visit 18.95 [33]
Ultrasound 73.75 [33]
Antiviral therapy
Peg interferon 8356.55 [34]
Entecavir 4595.35 [34]
Tenofovir 3062.35 [34]
Inactive carriers 223.90 Calculated as below*
Disease state
Chronic hepatitis B 1977.02 [35]
Compensated cirrhosis 3384.56 [35]
Decompensated cirrhosis 3384.56 [35]
Hepatocellular carcinoma 6808.71 [35]
Liver transplantation 82 867.40 [35]
Follow-up post-transplantation 6358.04 [36]
*Taking into account the cost of three tests a year on HBV DNA and transaminases; one check-up visit a  year, one upper abdominal ultrasound and one blood 
count.































HbsAg loss 1 year 2.33 9.32 6.99
2 years 1.07 4.28 3.21
3 years 1.12 4.48 3.36
4 years 1.66 4.66 3
5 years 1.21 4.84 3.63
Total cases of HbsAg loss 7.39 27.58 20.19
Undetectable
HBV DNA
1 year 2 184.62 2 349.34 164.72
2 years 2 192.67 2 342.79 150.12
3 years 2 198.15 2 334.99 136.84
4 years 2 201.34 2 325.82 124.48
5 years 2 202.51 2 315.43 112.92
Total inactive carriers   10 979.29 11 668.37 689.08
Chronic hepatitis B 1 year 906.08 748.47 -157.61
2 years 854.69 721.26 -133.43
3 years 808.27 697.04 -111.23
4 years 766.33 675.46 -90.87
5 years 728.36 656.24 -72.12
Total chronic hepatitis B cases 4 063.73 3 498.47 -565.26
Cirrhosis 1 year 144.65 133.33 -11.32
2 years 169.80 148.42 -21.38
3 years 190.26 160.51 -29.75
4 years 206.70 170.04 -36.66
5 years 219.68 177.39 -42.29
Total cirrhosis cases 931.09 789.69 -141.4
Decompensated cirrhosis 1 year 3.60 3.12 -0.48
2 years 6.89 5.83 -1.06
3 years 9.78 8.07 -1.71
4 years 12.27 9.90 -2.37
5 years 14.37 11.37 -3
Total decompensated cirrhosis cases 46.91 38.29 -8.62
Hepatocellular carcinoma 1 year 6.48 5.61 -0.87
2 years 11.25 9.27 -1.98
3 years 14.87 11.96 -2.91
4 years 17.65 13.97 -3.68
5 years 19.79 15.48 -4.31
Total HCC cases 70.04 56.29 -13.75
Liver transplant 1 year 0  0 0
2 years 0.25 0.27 0.02
3 years 0.48 0.47 -0.01
4 years 1.24 0.63 -0.61
5 years 1.52 1.21 -0.31
Total liver transplants 3.49 2.58 -0.91
Death 1 year 4.18 3.05 -1.13
2 years 8.82 7.43 -1.39
3 years 12.37 10.05 -2.32
4 years 15.23 12.11 -3.12
5 years 17.55 13.72 -3.83
Total deaths 58.15 46.36 -11.79































of  efforts  to  ensure  the  early  diagnosis  and  manage-
ment of this chronic disease in the province of Padua’s 
immigrant population. Several previous studies on this 
issue  involved  cost-effectiveness  analyses  [8,  9].  It  is 







Costs with screening (€, 2010)
1st year 2nd year 3rd year 4th year 5th year Total
HbsAg loss 93 516 41 690 42 336 42 812 43 132 263 486
Inactive carriers 232 843 223 122 213 807 204 881 196 328 1 070, 982
Chronic hepatitis B 1 293 171 1 316 961 1 335 340 1 348 761 1 357 673 6 651 907
Cirrhosis 277 147 256 814 238 371 221 645 206 466 1 200 444
Decompensated cirrhosis 19 519 35 455 47 606 56 679 63, 256 222 515
Hepatocellular carcinoma 35 119 56 299 70 569 80 039  86 101 328 127
Liver transplant 0.00 21 686 36 953 48 159 89 843 96 642
Death 9 557 22 576 29 660 34 669 38 154 134 616
Total 1 960 872 1 974 604 2 014 644 2 037 647 2 080 952 10 068 719
Cost of screening 797 681
Cost of HBV testing+ antiHBV vaccination 
for  cohabitants 
683 381
Total cost 11 549 781.29
Costs without screening (€)
1st year 2nd year 3rd year 4th year 5th year Total
HbsAg loss 23 379 10 422 10 584 10 703 10 772 65 861
Inactive carriers 58 211 55 781 53 452 51 220 49 082 267 745
Chronic hepatitis B 323 293 329 240 333 835 337 190 339 114 1 662 673
Cirrhosis 69 287 64 203 59 593 55 411 51 624 300 118
Decompensated cirrhosis 22 511 41 845 57 693 70 271 79 917 272 237
Hepatocellular carcinoma 28 067 68 342 87 749 101 125 110 076 395 360
Liver transplant 0.00 20 481 37 408 94 700 112 368 264 957
Death 19 326 26 798 36 488 43 611 48 802 175,025
Total 544 073 617 113 676 802 764 233 801 756 3 403 977
Cost of HBV testing + antiHBV vaccination 
for cohabitants 
170 845
Total cost 3 574 822
Table 6
Results of sensitivity analysis
No screening 20% adherence 40% adherence 60% adherence
Undetectable HBV DNA 6.9 14.3 27.6 43.0
Death 58.1 54.2 46.4 38.5
Lives saved 4.0 11.8 19.6
Costs € 3 577 791.42 € 7 135 509.79 € 11 549 781.27 € 16 178 532.08
Delta cost € 3 557 718.36 € 7 971 989.85 € 12 600 740.66
Cost per life saved € 898 287.72 € 676 709.47 € 641 659.52






























Our  study has  some  limitations. First  of  all,  it  only 
simulated a stable cohort, not a dynamic one. The study 
also fails to take into account the impact (in terms of 





of HBV  [42].  Another  weakness  of  our  study  lies  in 




complications  become manifest)  would  be  cost-effec-
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